General Pharmacology — MCQs

General Pharmacology Indian Medical PG Practice Questions and MCQs

Question 411: When used in the management of inflammatory disorders, glucocorticoids are likely to cause which of the following?

A. Hypoglycemia
B. Decreases in blood pressure
C. Anabolic actions in wound healing
D. Increase in intraocular pressure (Correct Answer)

Explanation: **Explanation:** Glucocorticoids (GCs) are steroid hormones that exert widespread metabolic and physiological effects. The correct answer is **D. Increase in intraocular pressure (IOP).** **Why it is correct:** Glucocorticoids can cause ocular hypertension and secondary open-angle glaucoma. They increase IOP by increasing the resistance to aqueous humor outflow through the trabecular meshwork. This occurs due to the accumulation of glycosaminoglycans and specific proteins (like myocilin) in the trabecular meshwork, which obstructs drainage. **Why the other options are incorrect:** * **A. Hypoglycemia:** GCs are "diabetogenic." They stimulate gluconeogenesis and decrease peripheral glucose uptake, leading to **hyperglycemia**, not hypoglycemia. * **B. Decreases in blood pressure:** GCs have weak mineralocorticoid activity, leading to sodium and water retention. They also sensitize vascular smooth muscle to catecholamines, typically causing **hypertension**. * **C. Anabolic actions in wound healing:** GCs are primarily **catabolic**. They inhibit fibroblast proliferation and collagen synthesis, which leads to delayed wound healing and skin thinning (striae). **High-Yield Clinical Pearls for NEET-PG:** * **Cushingoid Side Effects:** Remember the mnemonic **"CUSHINGOID"**: **C**ataracts (Posterior Subcapsular), **U**lcers (Peptic), **S**triate/Skin thinning, **H**ypertension/Hirsutism, **I**mmunosuppression, **N**ecrosis (Avascular necrosis of femoral head), **G**lucose elevation, **O**steoporosis, **I**OP increase, **D**epression/Psychosis. * **Osteoporosis:** GCs are the most common cause of drug-induced osteoporosis (they inhibit osteoblasts and decrease calcium absorption). * **Growth:** In children, GCs cause growth retardation due to interference with growth hormone action and epiphyseal closure.

Question 412: Drugs used for rare diseases are known as:

A. Orphan drugs (Correct Answer)
B. Rare drugs
C. Over-the-counter drugs
D. Emergency drugs

Explanation: **Explanation:** **1. Why "Orphan Drugs" is correct:** Orphan drugs are biological products or medicines intended for the diagnosis, prevention, or treatment of **rare diseases** (e.g., Cystic Fibrosis, Gaucher’s disease, Thalidomide for Leprosy). These diseases affect a very small percentage of the population. Because the market for these drugs is limited, pharmaceutical companies find them commercially non-viable to develop under normal conditions. To encourage their production, governments provide incentives like tax credits, patent extensions, and simplified marketing authorization. **2. Why other options are incorrect:** * **Rare drugs:** This is a distractor term. While the diseases are rare, the pharmacological classification for the treatment is "Orphan drug," not "rare drug." * **Over-the-counter (OTC) drugs:** These are non-prescription drugs that can be sold directly to a consumer without a doctor's note (e.g., Paracetamol, Antacids). They are used for common, self-limiting conditions, the opposite of rare diseases. * **Emergency drugs:** These are life-saving medications required for immediate administration in acute conditions (e.g., Adrenaline in anaphylaxis, Atropine in organophosphate poisoning). Their classification is based on the urgency of use, not the prevalence of the disease. **3. High-Yield Clinical Pearls for NEET-PG:** * **Definition Criteria:** In the USA, a rare disease is defined as one affecting fewer than **200,000 people**. * **Examples of Orphan Drugs:** * **Digoxin Immune Fab:** For Digoxin toxicity. * **Fomepizole:** For Methanol poisoning. * **Amphotericin B:** For Visceral Leishmaniasis (Kala-azar). * **Thalidomide:** For Type 2 Lepra reaction (ENL) [1]. * **Regulatory Act:** The Orphan Drug Act was first passed in the USA in 1983.

Question 413: Which of the following represents the newest therapeutic drug development agent?

A. Ribozyme
B. Micro RNA (Correct Answer)
C. SnRNA
D. Retro RNA

Explanation: **Explanation:** The correct answer is **Micro RNA (miRNA)**. In the landscape of modern pharmacology, RNA-based therapeutics represent the "third wave" of drug development (following small molecules and biologics). **Why Micro RNA is correct:** Micro RNAs are small, non-coding RNA molecules (approx. 22 nucleotides) that regulate gene expression post-transcriptionally by binding to messenger RNA (mRNA). This leads to translational repression or target degradation. The development of **miRNA mimics** (to replace lost tumor suppressors) and **antagomirs** (to inhibit disease-causing miRNAs) is currently at the forefront of precision medicine, particularly in oncology, cardiology, and antiviral therapy (e.g., Miravirsen for Hepatitis C). **Analysis of Incorrect Options:** * **Ribozymes:** These are RNA molecules with enzymatic activity (e.g., hammerhead ribozymes). While they were explored for gene silencing in the 1990s, their clinical utility has been largely superseded by more stable RNAi technologies. * **SnRNA (Small Nuclear RNA):** These are involved in the splicing of pre-mRNA within the nucleus (forming spliceosomes). While vital for cell biology, they are not primary targets for "newest" drug development compared to the miRNA/siRNA classes. * **Retro RNA:** This is not a standard pharmacological term for a therapeutic agent; it likely refers to retrotransposons or the reverse transcription process, which are mechanisms of genetic movement rather than drug classes. **NEET-PG High-Yield Pearls:** * **siRNA vs. miRNA:** siRNA (Small Interfering RNA) is perfectly complementary to its target mRNA and causes direct cleavage, whereas miRNA often has imperfect pairing and acts via translational repression. * **Patisiran:** The first-ever FDA-approved siRNA drug (targeting transthyretin for amyloidosis). * **Delivery Challenge:** The biggest hurdle for RNA drugs is delivery; they are often packaged in **Lipid Nanoparticles (LNPs)** to prevent degradation by RNAses.

Question 414: What is pharmacokinetics?

A. The study of absorption, distribution, binding, storage, biotransformation, and excretion of drugs. (Correct Answer)
B. The study of the physiological and biochemical effects of drugs.
C. The application of pharmacological information together with knowledge of the disease.
D. The scientific study of drugs in humans.

Explanation: **Explanation:** Pharmacokinetics refers to the quantitative study of drug movement in, through, and out of the body. It is often simplified as **"what the body does to the drug."** 1. **Why Option A is Correct:** Pharmacokinetics encompasses the processes of **ADME**: **A**bsorption, **D**istribution, **M**etabolism (biotransformation), and **E**xcretion. It involves the mathematical assessment of drug concentration over time, including how drugs bind to plasma proteins and are stored in tissues. 2. **Analysis of Incorrect Options:** * **Option B:** This defines **Pharmacodynamics**, which is "what the drug does to the body" (mechanism of action and physiological effects). * **Option C:** This defines **Pharmacotherapeutics**, the clinical application of drugs to treat diseases. * **Option D:** This defines **Clinical Pharmacology**, the study of drugs specifically in human subjects (both healthy volunteers and patients). **High-Yield NEET-PG Pearls:** * **Zero-order kinetics:** A constant *amount* of drug is eliminated per unit time (e.g., Alcohol, Phenytoin, Salicylates). * **First-order kinetics:** A constant *fraction* of drug is eliminated per unit time (most drugs follow this). * **Bioavailability:** The fraction of an administered dose that reaches the systemic circulation in unchanged form. * **Volume of Distribution (Vd):** A theoretical volume that relates the amount of drug in the body to its plasma concentration. Drugs with high Vd (e.g., Digoxin, Chloroquine) are sequestered in tissues and cannot be removed by hemodialysis.

Question 415: What is the duration of Phase IV in clinical trials?

A. 3-5 years
B. 1-3 years
C. 1 year
D. Indefinite duration (Correct Answer)

Explanation: ### Explanation **Correct Answer: D. Indefinite duration** **1. Why "Indefinite duration" is correct:** Phase IV clinical trials, also known as **Post-Marketing Surveillance (PMS)**, begin after a drug has been approved by regulatory authorities (like the FDA or CDSCO) and is available on the market. Unlike Phases I, II, and III, which have specific protocols and fixed timelines to establish safety and efficacy for approval, Phase IV has no fixed endpoint. Its primary purpose is the continuous monitoring of the drug’s performance in the general population to detect **rare adverse effects**, long-term complications, and drug-drug interactions that may not have surfaced in the controlled, smaller cohorts of Phase III. As long as the drug remains on the market, Phase IV monitoring continues. **2. Why other options are incorrect:** * **Options A, B, and C:** These represent finite timeframes. While individual Phase IV *studies* might last 1–5 years, the **phase itself** is ongoing. Fixed durations are more characteristic of pre-marketing phases: * **Phase I:** Days to weeks. * **Phase II:** Months to ~2 years. * **Phase III:** 1 to 4 years. **3. High-Yield Clinical Pearls for NEET-PG:** * **Primary Goal:** To detect **Rare Adverse Events** (e.g., incidence < 1 in 10,000). * **Population:** Open-ended; includes special groups (elderly, children, pregnant women) usually excluded from earlier phases. * **Pharmacovigilance:** This is the core activity of Phase IV. It can lead to "Black Box Warnings" or the withdrawal of a drug (e.g., Rofecoxib due to cardiovascular risks). * **Phase V:** Sometimes used to describe translational research or population-level effectiveness studies, though not a standard regulatory term.

Question 416: All of the following induce liver microsomal enzymes except?

A. Metyrapone (Correct Answer)
B. Glutethimide
C. Carbamazepine
D. Phenobarbitone

Explanation: **Explanation:** The core concept tested here is the distinction between **Enzyme Inducers** and **Enzyme Inhibitors** within the Cytochrome P450 (CYP450) system. **Why Metyrapone is the Correct Answer:** Metyrapone is a diagnostic drug used to test pituitary-adrenal function. Mechanistically, it acts as a **microsomal enzyme inhibitor**, specifically inhibiting the enzyme **11-β-hydroxylase**. This inhibition blocks the conversion of 11-deoxycortisol to cortisol. Because it inhibits rather than induces hepatic enzymes, it is the "except" in this list. **Analysis of Incorrect Options (Enzyme Inducers):** * **Phenobarbitone:** A classic, potent inducer of multiple CYP450 isoenzymes. It is often the "prototype" inducer mentioned in textbooks. * **Carbamazepine:** A well-known anti-epileptic that is a strong inducer; it is unique because it exhibits **auto-induction** (induces its own metabolism). * **Glutethimide:** An older sedative-hypnotic drug that is a documented hepatic microsomal enzyme inducer. **High-Yield Clinical Pearls for NEET-PG:** To remember common **Enzyme Inducers**, use the mnemonic **"GPRS Cell Phone"**: * **G**riseofulvin * **P**henytoin / **P**henobarbitone * **R**ifampicin (Most potent inducer) * **S**moking / **S**t. John’s Wort * **C**arbamazepine * **P**henobarbitone **Clinical Significance:** Enzyme induction leads to decreased plasma concentrations of co-administered drugs (e.g., failure of oral contraceptives or subtherapeutic warfarin levels), whereas inhibition (like with Metyrapone, Ketoconazole, or Cimetidine) leads to increased drug toxicity.

Question 417: Which of the following statements is NOT true of local anesthetics?

A. The local anesthetic is required in the unionized form for penetrating the neuronal membrane.
B. The local anesthetic approaches its receptor only from the intraneuronal face of the Na+ channel.
C. The local anesthetic binds to its receptor mainly when the Na+ channel is in the resting state. (Correct Answer)
D. The local anesthetic combines with its receptor in the ionized cationic form.

Explanation: ### Explanation Local anesthetics (LAs) are weak bases that exist in an equilibrium between an **unionized (B)** and an **ionized (BH+)** form [3]. Their mechanism of action depends on their ability to cross the lipid bilayer and block voltage-gated sodium (Na+) channels [4]. **1. Why Option C is the correct answer (The False Statement):** Local anesthetics exhibit **"Use-dependent" or "State-dependent" blockade** [1]. They have a much higher affinity for Na+ channels when they are in the **Activated (Open)** or **Inactivated** states rather than the Resting state [1]. In the resting state, the channel receptor is less accessible. This is why LAs are more effective in rapidly firing neurons (e.g., during pain transmission). **2. Analysis of Incorrect Options (True Statements):** * **Option A:** To reach their site of action, LAs must cross the lipid-rich neuronal membrane. Only the **unionized (lipophilic) form** can diffuse across this membrane [3]. * **Option B:** Most LAs are "hydrophilic pathway" blockers. They must enter the cell first and then bind to the receptor located on the **inner (cytoplasmic) mouth** of the Na+ channel [2]. * **Option C:** Once inside the axoplasm, the LA re-equilibrates. It is the **ionized cationic form (BH+)** that actually binds to the receptor and stabilizes the channel in the inactivated state, preventing depolarization [3]. ### NEET-PG High-Yield Pearls * **pH Effect:** In inflamed/infected tissues (acidic pH), LAs become more ionized outside the cell, reducing their ability to penetrate the membrane, leading to **decreased efficacy** [3]. * **Order of Blockade:** Small myelinated fibers (Aδ) and unmyelinated fibers (C) are blocked first [2], [3]. Clinically, the sequence is: **Pain > Temperature > Touch > Deep Pressure > Motor.** * **Bupivacaine:** Notable for its **cardiotoxicity** (blocks cardiac Na+ channels during diastole) [2]. Intravenous lipid emulsion (LipidRescue) is the antidote. * **Benzocaine:** Can cause **methemoglobinemia**.

Question 418: Thalidomide is used in which of the following conditions?

A. Lepra reaction
B. Multiple Myeloma
C. Ulcerative Colitis
D. All of the above (Correct Answer)

Explanation: Thalidomide, once infamous for its teratogenic effects (phocomelia), has been repurposed in modern medicine due to its potent **anti-inflammatory, immunomodulatory, and anti-angiogenic** properties. It acts primarily by inhibiting Tumor Necrosis Factor-alpha (TNF-α) and modulating T-cell responses. **Explanation of Options:** * **Lepra Reaction (ENL):** Thalidomide is the drug of choice for Type 2 Lepra Reaction (Erythema Nodosum Leprosum). It effectively suppresses the systemic inflammatory response by inhibiting TNF-α. * **Multiple Myeloma:** It is a cornerstone in the treatment of refractory or newly diagnosed Multiple Myeloma. Its mechanism involves inhibiting angiogenesis in the bone marrow and inducing apoptosis of malignant plasma cells. * **Ulcerative Colitis:** Due to its TNF-α inhibitory action, thalidomide is used as an "off-label" or reserve treatment for refractory cases of Inflammatory Bowel Disease (IBD), including Ulcerative Colitis and Crohn’s disease, when standard therapies fail. **Clinical Pearls for NEET-PG:** 1. **Mechanism:** Inhibition of TNF-α and IL-12; stimulation of T-cells (CD8+); and anti-angiogenic activity (via inhibition of VEGF and bFGF). 2. **Teratogenicity:** It is a category X drug. It causes **Phocomelia** (seal-like limbs) by inhibiting angiogenesis in developing limb buds. 3. **STEPS Program:** Due to its high teratogenic risk, it is prescribed under a restricted distribution program (System for Thalidomide Education and Prescribing Safety). 4. **Side Effects:** Peripheral neuropathy (most common dose-limiting toxicity), sedation, and increased risk of venous thromboembolism (especially when used with dexamethasone in Myeloma).

Question 419: Cyclosporine inhibits which of the following?

A. T lymphocyte proliferation (Correct Answer)
B. B lymphocyte proliferation
C. Both T and B lymphocyte proliferation
D. NK cells only

Explanation: **Explanation:** **Mechanism of Action (Why A is correct):** Cyclosporine is a potent **calcineurin inhibitor**. Under normal physiological conditions, an increase in intracellular calcium activates calcineurin (a phosphatase). Calcineurin then dephosphorylates the **Nuclear Factor of Activated T-cells (NFAT)**, allowing it to enter the nucleus and initiate the transcription of **Interleukin-2 (IL-2)**. IL-2 is the primary cytokine responsible for the proliferation and differentiation of T lymphocytes. By binding to cyclophilin, Cyclosporine forms a complex that inhibits calcineurin, thereby blocking IL-2 production and specifically halting **T lymphocyte proliferation**. **Analysis of Incorrect Options:** * **Option B & C:** Cyclosporine is highly selective for T-cells. It does not significantly inhibit B lymphocyte proliferation directly, as B-cell activation involves different signaling pathways that are less dependent on the calcineurin-NFAT axis. * **Option D:** While Cyclosporine may have minor downstream effects on the immune cascade, its primary and therapeutic target is the T-helper cell (CD4+), not Natural Killer (NK) cells. **High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Uses:** Prevention of graft-versus-host disease (GVHD) in organ transplants and treatment of autoimmune conditions like rheumatoid arthritis and psoriasis. * **Adverse Effects (The "H" Mnemonic):** **H**ypertension, **H**yperplasia of gums (gingival hyperplasia), **H**irsutism, and **H**yperkalemia. * **Most Serious Side Effect:** Nephrotoxicity (dose-related and usually reversible). * **Metabolism:** It is metabolized by **CYP3A4**; therefore, grapefruit juice (an inhibitor) can increase its toxicity.

Question 420: A patient requires ceftriaxone 180 mg. You have a 2 mL syringe with 10 divisions per mL. The vial contains 500 mg/5 mL of ceftriaxone. How many divisions in the 2 mL syringe will you fill to give 180 mg ceftriaxone?

A. 18 (Correct Answer)
B. 1.8
C. 20
D. 2

Explanation: ### Explanation This question tests the ability to perform **pharmaceutical calculations**, a vital skill for clinical practice and a high-yield area in General Pharmacology. **1. Why Option A is Correct:** To find the number of divisions, we follow a two-step calculation: * **Step 1: Calculate the volume required.** The vial concentration is $500\text{ mg}$ in $5\text{ mL}$, which simplifies to $100\text{ mg/mL}$. Using the formula: $\text{Volume} = \frac{\text{Desired Dose}}{\text{Concentration on Hand}}$ $\text{Volume} = \frac{180\text{ mg}}{100\text{ mg/mL}} = \mathbf{1.8\text{ mL}}$ * **Step 2: Convert volume into syringe divisions.** The syringe has $10\text{ divisions per mL}$. Total divisions = $\text{Volume (mL)} \times \text{Divisions per mL}$ Total divisions = $1.8\text{ mL} \times 10 = \mathbf{18\text{ divisions}}$ **2. Why the Other Options are Incorrect:** * **Option B (1.8):** This represents the volume in **milliliters (mL)**, not the number of divisions. * **Option C (20):** This would be the total capacity of the $2\text{ mL}$ syringe ($2 \times 10 = 20$), delivering $200\text{ mg}$. * **Option D (2):** This is a mathematical error, likely from miscalculating the concentration or the division factor. **3. Clinical Pearls & High-Yield Facts:** * **Ceftriaxone Specifics:** It is a third-generation cephalosporin. **High-yield fact:** Avoid diluting Ceftriaxone with **Calcium-containing solutions** (like Ringer’s Lactate) as it can form fatal precipitates, especially in neonates. * **Calculation Tip:** Always double-check the "units" requested (mL vs. mg vs. divisions). In NEET-PG, "divisions" usually refers to the smallest markings on a syringe (often $0.1\text{ mL}$ in a $2\text{ mL}$ or $5\text{ mL}$ syringe). * **Pediatric Dosing:** Most errors occur during the conversion from stock concentration to the final volume; always use the $C_1V_1 = C_2V_2$ or the "Desired/Have" formula.

Practice by Chapter

Pharmacokinetics: Absorption and Distribution

Practice Questions

Pharmacokinetics: Metabolism and Excretion

Practice Questions

Pharmacodynamics and Receptor Theory

Practice Questions

Drug-Receptor Interactions and Dose-Response

Practice Questions

Pharmacogenetics and Personalized Medicine

Practice Questions

Adverse Drug Reactions and Toxicity

Practice Questions

Drug Interactions

Practice Questions

Drug Development and Regulation

Practice Questions

Pediatric and Geriatric Pharmacology

Practice Questions

Placental Transfer and Lactation

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free